Health Canada granted a Notice of Compliance with Conditions for LEQEMBI (lecanemab), authorizing the anti‑amyloid monoclonal antibody for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are ApoE ε4 non‑carriers or heterozygotes and have confirmed amyloid pathology. Eisai and Biogen framed the authorization as the first Canadian approval of a therapy shown to slow clinical decline in early AD. The approval aligns Canada with other jurisdictions (U.S., EU, Japan) that have authorized lecanemab under defined populations and monitoring requirements. Company statements emphasized plans to work with stakeholders to enable timely patient access and to support diagnostic capacity and appropriate use within clinical pathways.